Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)Nizar M. Tannir, Oleg Karyakin, Maria Nirvana Formiga et al.|Journal of Clinical Oncology|2024Cited by 26
Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.Ziad Bakouny, Toni K. Choueiri, Ajjai Alva et al.|Journal of Clinical Oncology|2020Cited by 20
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Chun Loo Gan, Daniel Yick Chin Heng, Shaan Dudani et al.|Journal of Clinical Oncology|2021Cited by 11
Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).Sumanta K. Pal, Sun Young Rha, Javier Puente et al.|Journal of Clinical Oncology|2021Cited by 11
Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.Cristiane Decat Bergerot, Javier Puente, Sun Young Rha et al.|Journal of Clinical Oncology|2021Cited by 1